The content on this site is intended for healthcare professionals only
Dr Mike Cusnir, speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium and discusses the pancreatobiliary advances that happened.
The pancreatic arena has been slow developing data, but he discusses the interesting new information and developments that will impact patients lives.
Dr Cusnir continues to discuss the increase in targetted therapies in pancreatic cancer.
New classification for identifying HR myeloma based on cytogenetic abnormalities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Synthetic biology and precision medicine in blood and gynaecological cancers
Relapsed refractory multiple myeloma
Liquid biopsies and cancer: The role of NGS, CTC, exosomes, cfDNA and cfRNA
Molecular oncology and translational medicine
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Molecular profiling in prostate cancer: key challenges for clinical implementation
